Bukwang Pharmaceutical Co., Ltd.
https://www.bukwang.co.kr/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bukwang Pharmaceutical Co., Ltd.
Bukwang Adds To Stacking Mid-Stage Failures In Parkinson's
Bukwang and subsidiary Contera have become the latest to fail to progress a novel Parkinson's therapy to late-stage trials after a Phase II miss, although several other Korean firms remain in the race for the challenging indication, albeit mainly in Phase I-II.
Hanmi's Merger Plan Could Spark Power Struggle In South Korea Pharma Sector
An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.
Hanmi Announces Merger While Possible Power Struggle Surfaces
An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.
Deal Watch: Vanda Buys US, Canadian Rights To J&J’s Ponvory
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- Concit Pharma ApS
- Contera Pharma
- Dyna Therapeutics Co., Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice